Welcome to our dedicated page for Naturl Alt Intl news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Naturl Alt Intl stock.
The Natural Alternatives International, Inc. (NAII) news page on Stock Titan aggregates company announcements, earnings releases, and regulatory updates for investors following this nutritional supplements manufacturer. NAI describes itself as a formulator, manufacturer, and marketer of customized nutritional supplements, with operations that include private-label contract manufacturing and patent and trademark licensing related to proprietary ingredients such as CarnoSyn® beta-alanine and TriBsyn™.
News items commonly include quarterly and annual financial results, where NAI reports net sales, segment performance for private-label contract manufacturing and CarnoSyn® beta-alanine royalty, licensing and raw material sales, and commentary on factors affecting profitability such as factory capacity utilization, sales mix, and operating costs. These releases also provide information on cash balances, working capital, and borrowing capacity under the company’s credit facility.
Investors can also find corporate and commercial updates, such as new or amended manufacturing agreements and distribution partnerships. For example, NAI has announced a multi-year Manufacturing Agreement with The Juice Plus+ Company covering capsule and powder products sold in over 24 markets, and a U.S. distribution agreement for TriBsyn™ with B&D Nutritional Ingredients. Such news highlights NAI’s customer relationships and the commercial rollout of its proprietary ingredients.
Another category of news covers product and scientific developments. NAI and CarnoSyn® Brands have issued press releases about clinical research on TriBsyn™, including a published study demonstrating increased beta-alanine bioavailability and elimination of paresthesia, as well as participation in scientific conferences like the ESPEN Congress on Clinical Nutrition & Metabolism.
By reviewing this news feed, readers can track NAII earnings announcements, material agreements, scientific milestones, and other company communications in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Natural Alternatives International, Inc. (NAII) announced the publication of a new study in Nutrients demonstrating the cognitive benefits of SR CarnoSyn® beta-alanine tablets in older adults. Conducted with 100 participants aged 60-80, the double-blind study revealed significant improvements in cognitive function and reduced depression scores among those with baseline cognitive challenges. The study utilized a 600 mg tablet dosage, providing 2.4 grams daily. This research supports the extensive benefits of CarnoSyn® beta-alanine, already shown to enhance executive function and reduce mental fatigue, further solidifying NAII's commitment to science-backed nutritional supplements.
Natural Alternatives International (NAII) reported net income of $1.8 million, or $0.31 per diluted share, on $42.3 million in net sales for Q2 FY2023, an increase of 12.1% year-over-year. Private-label contract manufacturing sales surged 21.3% to $40.8 million. However, CarnoSyn® beta-alanine revenue fell 64%, reflecting a slowdown in the Sports Nutrition sector. For the first half of FY2023, net income decreased to $2.9 million from $5.1 million, with sales forecasts indicating a slight decline for the full fiscal year. The company is facing inflationary pressures and increased operational costs, negatively impacting profitability. Construction on a new plant in California is set to complete by spring 2023.
Natural Alternatives International, Inc. (NAII) has authorized a $1.0 million increase in its stock repurchase plan, raising the total to $19.0 million. This allows for continued buybacks based on market conditions. NAII has already repurchased 2.1 million shares and has $1.2 million remaining for future purchases. CEO Mark A. Le Doux expressed confidence in the company's value and growth, highlighting the upcoming operational launch of their new facility in Carlsbad, CA.
Natural Alternatives International (NAII) reported a net income of $1.1 million for Q1 FY 2023, down from $3.3 million in Q1 FY 2022. Net sales increased by 12.5% to $43.1 million compared to $38.3 million last year, driven mainly by a 24.4% rise in private-label contract manufacturing. However, CarnoSyn® beta-alanine revenues dropped 71.5% to $1.4 million, impacted by inflation and a slowdown in the Sports Nutrition sector. Although NAII anticipates slight sales growth for FY 2023, operating income may suffer due to rising costs and unfavorable currency effects.
Natural Alternatives International, Inc. (NAII) reported a strong performance in Q4 2022, achieving $52.5 million in net sales, up 18.3% year-over-year. Net income rose to $3.1 million or $0.52 per diluted share, compared to $3.0 million and $0.47 in Q4 2021. However, overall annual sales decreased 4.2% to $171 million. The company anticipates 10%-15% net sales growth for fiscal 2023, but warns of potential operating income impacts due to inflation and rising operational costs. They also outlined ongoing challenges in their supply chain and have begun constructing a new manufacturing facility.
Natural Alternatives International (NAII) reported a 30.7% increase in net income for Q3 FY2022, totaling $2.5 million or $0.41 per diluted share. Net sales, however, fell 8.5% to $42.4 million, driven by a 10.8% drop in private-label contract manufacturing sales due to a 40% reduction in sales from its largest customer. Despite ongoing supply chain issues, NAII anticipates 18%-21% growth in net sales for Q4 FY2022. The company holds $18.6 million in cash and a working capital of $53.8 million, showcasing resilience amid challenges.